The state-of-the-art facility will be built at Muppireddipalli to manufacture Sanofi’s Insuman, a human insulin for diabetes patients
K Chandrasekhar Rao, Chief Minister, Telangana laid the foundation stone of Shantha, a Sanofi company’s new production facility. The facility will manufacture Insuman, a human insulin product from Sanofi’s range of diabetes treatments. Sanofi will invest Rs 460 crores in the facility. Located in Muppireddipalli (Telangana), the facility will be equipped with the latest technology and will be Sanofi’s second plant aside from the company’s existing Insuman manufacturing plant in Frankfurt. The construction of the 13,400 square-meter building will begin soon, with the site fully operational by 2019.
Dr Harish Iyer, Chief Executive Officer, Shantha Biotechnics said, “For the first time, we will be able to manufacture insulin – in cartridges here. The new high technology facility will benefit from our existing biotechnology production expertise. This facility will have the capability to ramp up manufacturing volumes to 60 million Insuman cartridges per year, within two to three years of commercial manufacturing.”
Dr Shailesh Ayyangar, Managing Director – India and Vice President – South Asia, Sanofi said, “We look forward to the successful 2/3 completion of the Insuman site construction, so that many more diabetic patients in India can have easier access to better disease management and quality of life.”
EP News Bureau – Mumbai